Compare FirstEnergy Corp. (FE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Sanofi SA — how do they compare? FirstEnergy Corp. trades at $44.9 (market cap $25.95B), while Sanofi SA trades at $40.02 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.7× FirstEnergy Corp.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and Sanofi SA for 94 Days on average.
| FE | SNY | |
|---|---|---|
Market Cap | $25.95B | $95.18B |
Volume | 5,643,833 | 2,995,646 |
Sector | Utilities | Health |
52-Week High | $51.91 | $52.34 |
52-Week Low | $43.04 | $39.51 |
Typical Hold Time | 71 Days | 94 Days |
Enterprise Value | $54.87B | $114.48B |
Dividend Yield | 4.15% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.58, up 0.72% with a bullish technical signal despite mixed earnings. The utility shows steady revenue growth to $15.09B in 2025 and maintains a 6.86% net margin, though recent quarters saw two EPS misses. Analyst consensus is Moderate Buy with a $52.80 target, while institutional interest grows with recent purchases by Nykredit and Corient Private Wealth.
FE offers stable utility operations with dividend support, but faces execution risks from its $36B Energize365 plan and rising debt. The stock's 8.4% upside to target and 4.2% dividend yield appeal to income investors, though high RSI suggests near-term pressure. Regulatory approvals and data-center demand are key catalysts.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
